HLA variants and inhibitor development in hemophilia A: results from the HEMFIL study group.
作者信息
Santana Márcio Antônio Portugal, Chaves Daniel Gonçalves, Souza Felipe Cb, Rezende Suely Meireles
机构信息
Fundação de Hematologia e Hemoterapia de Minas Gerais (Hemominas), Belo Horizonte, Minas Gerais, Brazil; Department of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Fundação de Hematologia e Hemoterapia de Minas Gerais (Hemominas), Belo Horizonte, Minas Gerais, Brazil.
出版信息
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S431-S434. doi: 10.1016/j.htct.2024.05.015. Epub 2024 Sep 20.
Abstract
摘要
相似文献
1
HLA variants and inhibitor development in hemophilia A: results from the HEMFIL study group.甲型血友病中的HLA变异与抑制剂的产生：HEMFIL研究小组的结果
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S431-S434. doi: 10.1016/j.htct.2024.05.015. Epub 2024 Sep 20.
2
Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study.血友病患儿抗体形成的风险因素：HEMFIL 队列研究的方法学方面和临床特征。
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):443-450. doi: 10.1097/MBC.0000000000001057.
3
Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.仅使用第三代重组凝血因子VIII浓缩剂时甲型血友病患者的抑制剂发生率：HEMFIL队列研究结果
Br J Haematol. 2019 Jul;186(1):152-155. doi: 10.1111/bjh.15728. Epub 2018 Dec 17.
4
HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset.血友病A中的HLA变异与抑制剂的产生：一项使用ATHN数据集的回顾性病例对照研究
Front Med (Lausanne). 2021 May 7;8:663396. doi: 10.3389/fmed.2021.663396. eCollection 2021.
5
HLA-DRB1*01:01, but not HLA-DRB1:1503 or HLA-DRB1*11, is associated with decreased inhibitor risk in Iranian hemophilia A patients.HLA-DRB1*01:01与伊朗甲型血友病患者中抑制剂风险降低相关，而HLA-DRB1:1503或HLA-DRB1*11则不然。
Transfus Apher Sci. 2019 Oct;58(5):669-673. doi: 10.1016/j.transci.2019.08.019. Epub 2019 Sep 16.
6
The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A.泰国血友病 A 患者 HLA Ⅱ类等位基因与因子 VIII 抑制剂发生的相关性研究。
Turk J Haematol. 2012 Mar;29(1):34-9. doi: 10.5505/tjh.2012.29795. Epub 2012 Mar 5.
7
Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.使用机器学习网络预测重度和中度重度甲型血友病初治及轻度治疗儿童中抑制剂的产生情况。
J Thromb Haemost. 2024 Sep;22(9):2426-2437. doi: 10.1016/j.jtha.2024.05.017. Epub 2024 May 27.
8
FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.FVIII 免疫原性-生物信息学方法评估非重度血友病 A 抑制剂风险。
Front Immunol. 2020 Jul 28;11:1498. doi: 10.3389/fimmu.2020.01498. eCollection 2020.
9
Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A.HLA I/II 基因型对汉族重型血友病 A 患者抑制物发生风险的影响：来自韩国患者的数据。
Ann Hematol. 2018 Sep;97(9):1695-1700. doi: 10.1007/s00277-018-3358-x. Epub 2018 May 16.
10
Effect of the First Factor VIII Infusions on Immunological Biomarkers in Previously Untreated Patients with Hemophilia A from the HEMFIL Study.HEMFIL研究中首次输注凝血因子VIII对既往未治疗的甲型血友病患者免疫生物标志物的影响。
Thromb Haemost. 2021 Jul;121(7):891-899. doi: 10.1055/s-0040-1722353. Epub 2021 Jan 10.
本文引用的文献
1
Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study.血友病患儿抗体形成的风险因素：HEMFIL 队列研究的方法学方面和临床特征。
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):443-450. doi: 10.1097/MBC.0000000000001057.
2
HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset.血友病A中的HLA变异与抑制剂的产生：一项使用ATHN数据集的回顾性病例对照研究
Front Med (Lausanne). 2021 May 7;8:663396. doi: 10.3389/fmed.2021.663396. eCollection 2021.
3
Development of inhibitors in hemophilia A: An illustrated review.血友病A抑制剂的研发：图文综述
Res Pract Thromb Haemost. 2020 May 26;4(5):752-760. doi: 10.1002/rth2.12335. eCollection 2020 Jul.
4
High-Resolution HLA Typing of HLA-A, -B, -C, -DRB1, and -DQB1 in Kinh Vietnamese by Using Next-Generation Sequencing.运用新一代测序技术对京族越南人进行HLA-A、-B、-C、-DRB1和-DQB1的高分辨率HLA分型
Front Genet. 2020 Apr 30;11:383. doi: 10.3389/fgene.2020.00383. eCollection 2020.
5
HLA-DRB1*01:01, but not HLA-DRB1:1503 or HLA-DRB1*11, is associated with decreased inhibitor risk in Iranian hemophilia A patients.HLA-DRB1*01:01与伊朗甲型血友病患者中抑制剂风险降低相关，而HLA-DRB1:1503或HLA-DRB1*11则不然。
Transfus Apher Sci. 2019 Oct;58(5):669-673. doi: 10.1016/j.transci.2019.08.019. Epub 2019 Sep 16.
6
Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A.HLA I/II 基因型对汉族重型血友病 A 患者抑制物发生风险的影响：来自韩国患者的数据。
Ann Hematol. 2018 Sep;97(9):1695-1700. doi: 10.1007/s00277-018-3358-x. Epub 2018 May 16.
7
Sequences of 95 human haplotypes reveal extreme coding variation in genes other than highly polymorphic and .95个人类单倍型序列揭示了除高度多态性的[基因名称1]和[基因名称2]之外的其他基因中的极端编码变异。
Genome Res. 2017 May;27(5):813-823. doi: 10.1101/gr.213538.116. Epub 2017 Mar 30.
8
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.A 随机对照试验VIII 因子和中和抗体在血友病 A.
N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.
9
EpViX: A cloud-based tool for epitope reactivity analysis and epitope virtual crossmatching to identify low immunologic risk donors for sensitized recipients.EpViX：一种基于云的工具，用于表位反应性分析和表位虚拟交叉匹配，以识别致敏受者的低免疫风险供体。
Transpl Immunol. 2015 Nov;33(3):153-8. doi: 10.1016/j.trim.2015.09.006. Epub 2015 Nov 1.
10
The Association Between HLA Class II Alleles and the Occurrence of Factor VIII Inhibitor in Thai Patients with Hemophilia A.泰国血友病 A 患者 HLA Ⅱ类等位基因与因子 VIII 抑制剂发生的相关性研究。
Turk J Haematol. 2012 Mar;29(1):34-9. doi: 10.5505/tjh.2012.29795. Epub 2012 Mar 5.
Zotero 插件